Regulation of myokine expression: Role of exercise and cellular stress

Free Radical Biology and Medicine

Volumn 98, Issue , 2016, Pages 78-89

  Ost, Mario ^a   Coleman, Verena ^a   Kasch, Juliane ^a   Klaus, Susanne ^a  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

Author keywords

Endoplasmic reticulum; Exercise; FGF21; Integrated stress response; Mitochondrial disease; Myokine; Secretory proteins; Skeletal muscle

Indexed keywords

APELIN; CHITINASE 3 LIKE PROTEIN 1; CYTOKINE; DECORIN; FIBROBLAST GROWTH FACTOR 21; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 15; INTERLEUKIN 6; IRISIN; LEUKEMIA INHIBITORY FACTOR; METEORIN LIKE PROTEIN; MUSCLE PROTEIN; MUSCLIN; MYOKINE; MYONECTIN; MYOSTATIN; OSTEONECTIN; SECRETORY PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL STRESS; CYTOKINE PRODUCTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOPLASMIC RETICULUM STRESS; EXERCISE; HUMAN; METABOLIC DISORDER; MUSCLE TRAINING; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SKELETAL MUSCLE; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY;

ENDOPLASMIC RETICULUM STRESS; EXERCISE; GENE EXPRESSION REGULATION; HUMANS; MUSCLE PROTEINS; MUSCLE, SKELETAL; OXIDATIVE STRESS;

EID: 84966320616     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2016.02.018     Document Type: Article

References (174)

1. [1] Kujala, U.M., Evidence on the effects of exercise therapy in the treatment of chronic disease. Br. J. Sports Med. 43 (2009), 550–555.
2. [2] Anton, S.D., Karabetian, C., Naugle, K., Buford, T.W., Obesity and diabetes as accelerators of functional decline: can lifestyle interventions maintain functional status in high risk older adults?. Exp. Gerontol. 48 (2013), 888–897.
3. [3] Fiuza-Luces, C., Garatachea, N., Berger, N.A., Lucia, A., Exercise is the real polypill. Physiology (Bethesda) 28 (2013), 330–358.
4. [4] Kell, R.T., Bell, G., Quinney, A., Musculoskeletal fitness, health outcomes and quality of life. Sports Med. 31 (2001), 863–873.
5. [5] Ball, D., Metabolic and endocrine response to exercise: sympathoadrenal integration with skeletal muscle. J. Endocrinol. 224 (2015), R79–R95.
6. [6] Hartwig, S., Raschke, S., Knebel, B., Scheler, M., Irmler, M., Passlack, W., Muller, S., Hanisch, F.G., Franz, T., Li, X., Dicken, H.D., Eckardt, K., Beckers, J., de Angelis, M.H., Weigert, C., Haring, H.U., Al-Hasani, H., Ouwens, D.M., Eckel, J., Kotzka, J., Lehr, S., Secretome profiling of primary human skeletal muscle cells. Biochim. Biophys. Acta 1844 (2014), 1011–1017.
7. [7] Pedersen, B.K., Steensberg, A., Fischer, C., Keller, C., Keller, P., Plomgaard, P., Febbraio, M., Saltin, B., Searching for the exercise factor: is IL-6 a candidate?. J. Muscle Res. Cell Motil. 24 (2003), 113–119.
8. [8] Allen, R.G., Tresini, M., Oxidative stress and gene regulation. Free Radic. Biol. Med. 28 (2000), 463–499.
9. [9] Winterbourn, C.C., Reconciling the chemistry and biology of reactive oxygen species. Nat. Chem. Biol. 4 (2008), 278–286.
10. [10] Forman, H.J., Augusto, O., Brigelius-Flohe, R., Dennery, P.A., Kalyanaraman, B., Ischiropoulos, H., Mann, G.E., Radi, R., Roberts, L.J. 2nd, Vina, J., Davies, K.J., Even free radicals should follow some rules: a guide to free radical research terminology and methodology. Free Radic. Biol. Med. 78 (2015), 233–235.
11. [11] Radak, Z., Zhao, Z., Koltai, E., Ohno, H., Atalay, M., Oxygen consumption and usage during physical exercise: the balance between oxidative stress and ROS-dependent adaptive signaling. Antioxid. Redox Signal 18 (2013), 1208–1246.
12. [12] Ristow, M., Unraveling the truth about antioxidants: mitohormesis explains ROS-induced health benefits. Nat. Med. 20 (2014), 709–711.
13. [13] Radak, Z., Chung, H.Y., Goto, S., Exercise and hormesis: oxidative stress-related adaptation for successful aging. Biogerontology 6 (2005), 71–75.
14. [14] Wu, J., Ruas, J.L., Estall, J.L., Rasbach, K.A., Choi, J.H., Ye, L., Bostrom, P., Tyra, H.M., Crawford, R.W., Campbell, K.P., Rutkowski, D.T., Kaufman, R.J., Spiegelman, B.M., The unfolded protein response mediates adaptation to exercise in skeletal muscle through a PGC-1alpha/ATF6alpha complex. Cell Metab. 13 (2011), 160–169.
15. [15] Ogborn, D.I., McKay, B.R., Crane, J.D., Parise, G., Tarnopolsky, M.A., The unfolded protein response is triggered following a single, unaccustomed resistance-exercise bout. Am. J. Physiol. Regul. Integr. Comp. Physiol. 307 (2014), R664–R669.
16. [16] Lightfoot, A.P., Nagaraju, K., McArdle, A., Cooper, R.G., Understanding the origin of non-immune cell-mediated weakness in the idiopathic inflammatory myopathies - potential role of ER stress pathways. Curr. Opin. Rheumatol. 27 (2015), 580–585.
17. [17] Rayavarapu, S., Coley, W., Nagaraju, K., Endoplasmic reticulum stress in skeletal muscle homeostasis and disease. Curr. Rheumatol. Rep. 14 (2012), 238–243.
18. [18] Scheele, C., Nielsen, S., Pedersen, B.K., ROS and myokines promote muscle adaptation to exercise. Trends Endocrinol. Metab. 20 (2009), 95–99.
19. [19] Pedersen, B.K., Febbraio, M.A., Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat. Rev. Endocrinol. 8 (2012), 457–465.
20. [20] Peake, J.M., Della Gatta, P., Suzuki, K., Nieman, D.C., Cytokine expression and secretion by skeletal muscle cells: regulatory mechanisms and exercise effects. Exerc. Immunol. Rev. 21 (2015), 8–25.
21. [21] Yoon, J.H., Kim, J., Song, P., Lee, T.G., Suh, P.G., Ryu, S.H., Secretomics for skeletal muscle cells: a discovery of novel regulators?. Adv. Biol. Regul. 52 (2012), 340–350.
22. [22] Gleeson, M., Immune function in sport and exercise. J. Appl. Physiol. (1985) 103 (2007), 693–699.
23. [23] Mathur, N., Pedersen, B.K., Exercise as a mean to control low-grade systemic inflammation. Mediators Inflamm., 2008, 2008, 109502.
24. [24] Nimmo, M.A., Leggate, M., Viana, J.L., King, J.A., The effect of physical activity on mediators of inflammation. Diabetes Obes. Metab. 15:Suppl. 3 (2013), S51–S60.
25. [25] Blaauw, B., Schiaffino, S., Reggiani, C., Mechanisms modulating skeletal muscle phenotype. Compr. Physiol. 3 (2013), 1645–1687.
26. [26] Hood, D.A., Irrcher, I., Ljubicic, V., Joseph, A.M., Coordination of metabolic plasticity in skeletal muscle. J. Exp. Biol. 209 (2006), 2265–2275.
27. [27] Catoire, M., Mensink, M., Kalkhoven, E., Schrauwen, P., Kersten, S., Identification of human exercise-induced myokines using secretome analysis. Physiol. Genomics 46 (2014), 256–267.
28. [28] Hawley, J.A., Hargreaves, M., Joyner, M.J., Zierath, J.R., Integrative biology of exercise. Cell 159 (2014), 738–749.
29. [29] Egan, B., Zierath, J.R., Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metab. 17 (2013), 162–184.
30. [30] Harman, D., Aging: a theory based on free radical and radiation chemistry. J. Gerontol. 11 (1956), 298–300.
31. [31] Powers, S.K., Duarte, J., Kavazis, A.N., Talbert, E.E., Reactive oxygen species are signalling molecules for skeletal muscle adaptation. Exp. Physiol. 95 (2010), 1–9.
32. [32] Mason, S., Wadley, G.D., Skeletal muscle reactive oxygen species: a target of good cop/bad cop for exercise and disease. Redox Rep. 19 (2014), 97–106.
33. [33] Steinbacher, P., Eckl, P., Impact of oxidative stress on exercising skeletal muscle. Biomolecules 5 (2015), 356–377.
34. [34] Ristow, M., Schmeisser, K., Mitohormesis: promoting health and lifespan by increased levels of reactive oxygen species (ROS). Dose Response 12 (2014), 288–341.
35. [35] Yun, J., Finkel, T., Mitohormesis. Cell Metab 19 (2014), 757–766.
36. [36] Deldicque, L., Hespel, P., Francaux, M., Endoplasmic reticulum stress in skeletal muscle: origin and metabolic consequences. Exerc Sport Sci. Rev. 40 (2012), 43–49.
37. [37] Kim, H.J., Jamart, C., Deldicque, L., An, G.L., Lee, Y.H., Kim, C.K., Raymackers, J.M., Francaux, M., Endoplasmic reticulum stress markers and ubiquitin-proteasome pathway activity in response to a 200-km run. Med. Sci. Sports Exerc. 43 (2011), 18–25.
38. [38] Chaudhari, N., Talwar, P., Parimisetty, A., Lefebvre d'Hellencourt, C., Ravanan, P., A molecular web: endoplasmic reticulum stress, inflammation, and oxidative stress. Front Cell Neurosci., 8, 2014, 213.
39. [39] Harding, H.P., Zhang, Y., Zeng, H., Novoa, I., Lu, P.D., Calfon, M., Sadri, N., Yun, C., Popko, B., Paules, R., Stojdl, D.F., Bell, J.C., Hettmann, T., Leiden, J.M., Ron, D., An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol. Cell 11 (2003), 619–633.
40. [40] Tyynismaa, H., Carroll, C.J., Raimundo, N., Ahola-Erkkila, S., Wenz, T., Ruhanen, H., Guse, K., Hemminki, A., Peltola-Mjosund, K.E., Tulkki, V., Oresic, M., Moraes, C.T., Pietilainen, K., Hovatta, I., Suomalainen, A., Mitochondrial myopathy induces a starvation-like response. Hum. Mol. Genet. 19 (2010), 3948–3958.
41. [41] Kim, K.H., Jeong, Y.T., Oh, H., Kim, S.H., Cho, J.M., Kim, Y.N., Kim, S.S., Kim do, H., Hur, K.Y., Kim, H.K., Ko, T., Han, J., Kim, H.L., Kim, J., Back, S.H., Komatsu, M., Chen, H., Chan, D.C., Konishi, M., Itoh, N., Choi, C.S., Lee, M.S., Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat. Med. 19 (2013), 83–92.
42. [42] Keipert, S., Ost, M., Johann, K., Imber, F., Jastroch, M., van Schothorst, E.M., Keijer, J., Klaus, S., Skeletal muscle mitochondrial uncoupling drives endocrine cross-talk through the induction of FGF21 as a myokine. Am. J. Physiol. Endocrinol. Metab. 306 (2014), E469–E482.
43. [43] Miyake, M., Nomura, A., Ogura, A., Takehana, K., Kitahara, Y., Takahara, K., Tsugawa, K., Miyamoto, C., Miura, N., Sato, R., Kurahashi, K., Harding, H.P., Oyadomari, M., Ron, D., Oyadomari, S., Skeletal muscle-specific eukaryotic translation initiation factor 2alpha phosphorylation controls amino acid metabolism and fibroblast growth factor 21-mediated non-cell-autonomous energy metabolism. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol., 2015.
44. [44] Bluher, M., Mantzoros, C.S., From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism 64 (2015), 131–145.
45. [45] Febbraio, M.A., Pedersen, B.K., Contraction-induced myokine production and release: is skeletal muscle an endocrine organ?. Exerc. Sport Sci. Rev. 33 (2005), 114–119.
46. [46] Eckardt, K., Gorgens, S.W., Raschke, S., Eckel, J., Myokines in insulin resistance and type 2 diabetes. Diabetologia 57 (2014), 1087–1099.
47. [47] Raschke, S., Eckel, J., Adipo-myokines: two sides of the same coin–mediators of inflammation and mediators of exercise. Mediators Inflamm., 2013, 2013, 320724.
48. [48] Schering, L., Hoene, M., Kanzleiter, T., Jahnert, M., Wimmers, K., Klaus, S., Eckel, J., Weigert, C., Schurmann, A., Maak, S., Jonas, W., Sell, H., Identification of novel putative adipomyokines by a cross-species annotation of secretomes and expression profiles. Arch. Physiol. Biochem., 2015, 1–12.
49. [49] Bortoluzzi, S., Scannapieco, P., Cestaro, A., Danieli, G.A., Schiaffino, S., Computational reconstruction of the human skeletal muscle secretome. Proteins 62 (2006), 776–792.
50. [50] Russell, A.P., PGC-1alpha and exercise: important partners in combating insulin resistance. Curr. Diabetes Rev. 1 (2005), 175–181.
51. [51] Egan, B., O'Connor, P.L., Zierath, J.R., O'Gorman, D.J., Time course analysis reveals gene-specific transcript and protein kinetics of adaptation to short-term aerobic exercise training in human skeletal muscle. PLoS One, 8, 2013, e74098.
52. [52] Ferraro, E., Giammarioli, A.M., Chiandotto, S., Spoletini, I., Rosano, G., Exercise-induced skeletal muscle remodeling and metabolic adaptation: redox signaling and role of autophagy. Antioxid. Redox Signal 21 (2014), 154–176.
53. [53] Nisoli, E., Falcone, S., Tonello, C., Cozzi, V., Palomba, L., Fiorani, M., Pisconti, A., Brunelli, S., Cardile, A., Francolini, M., Cantoni, O., Carruba, M.O., Moncada, S., Clementi, E., Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals. Proc. Natl. Acad. Sci. USA 101 (2004), 16507–16512.
54. [54] McConell, G.K., Ng, G.P., Phillips, M., Ruan, Z., Macaulay, S.L., Wadley, G.D., Central role of nitric oxide synthase in AICAR and caffeine-induced mitochondrial biogenesis in L6 myocytes. J. Appl. Physiol. 108 (2010), 589–595.
55. [55] Bostrom, P., Wu, J., Jedrychowski, M.P., Korde, A., Ye, L., Lo, J.C., Rasbach, K.A., Bostrom, E.A., Choi, J.H., Long, J.Z., Kajimura, S., Zingaretti, M.C., Vind, B.F., Tu, H., Cinti, S., Hojlund, K., Gygi, S.P., Spiegelman, B.M., A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481 (2012), 463–468.
56. [56] Rao, R.R., Long, J.Z., White, J.P., Svensson, K.J., Lou, J., Lokurkar, I., Jedrychowski, M.P., Ruas, J.L., Wrann, C.D., Lo, J.C., Camera, D.M., Lachey, J., Gygi, S., Seehra, J., Hawley, J.A., Spiegelman, B.M., Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell 157 (2014), 1279–1291.
57. [57] Lambernd, S., Taube, A., Schober, A., Platzbecker, B., Gorgens, S.W., Schlich, R., Jeruschke, K., Weiss, J., Eckardt, K., Eckel, J., Contractile activity of human skeletal muscle cells prevents insulin resistance by inhibiting pro-inflammatory signalling pathways. Diabetologia 55 (2012), 1128–1139.
58. [58] Nikolic, N., Bakke, S.S., Kase, E.T., Rudberg, I., Flo Halle, I., Rustan, A.C., Thoresen, G.H., Aas, V., Electrical pulse stimulation of cultured human skeletal muscle cells as an in vitro model of exercise. PLoS One, 7, 2012, e33203.
59. [59] Raschke, S., Eckardt, K., Bjorklund Holven, K., Jensen, J., Eckel, J., Identification and validation of novel contraction-regulated myokines released from primary human skeletal muscle cells. PLoS One, 8, 2013, e62008.
60. [60] Weissenbach, J., Chernajovsky, Y., Zeevi, M., Shulman, L., Soreq, H., Nir, U., Wallach, D., Perricaudet, M., Tiollais, P., Revel, M., Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies. Proc. Natl. Acad. Sci. USA 77 (1980), 7152–7156.
61. [61] Pedersen, B.K., Febbraio, M.A., Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol. Rev. 88 (2008), 1379–1406.
62. [62] Gu, N., Guo, Q., Mao, K., Hu, H., Jin, S., Zhou, Y., He, H., Oh, Y., Liu, C., Wu, Q., Palmitate increases musclin gene expression through activation of PERK signaling pathway in C2C12 myotubes. Biochem. Biophys. Res. Commun. 467 (2015), 521–526.
63. [63] Steensberg, A., van Hall, G., Osada, T., Sacchetti, M., Saltin, B., Klarlund Pedersen, B., Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. Pt 1 J. Physiol. 529 (2000), 237–242.
64. [64] Gorgens, S.W., Hjorth, M., Eckardt, K., Wichert, S., Norheim, F., Holen, T., Lee, S., Langleite, T., Birkeland, K.I., Stadheim, H.K., Kolnes, K.J., Tangen, D.S., Kolnes, A.J., Jensen, J., Drevon, C.A., Eckel, J., The exercise-regulated myokine chitinase-3-like protein 1 stimulates human myocyte proliferation. Acta Physiol., 2015.
65. [65] Welc, S.S., Clanton, T.L., The regulation of interleukin-6 implicates skeletal muscle as an integrative stress sensor and endocrine organ. Exp. Physiol. 98 (2013), 359–371.
66. [66] Wright, V.P., Reiser, P.J., Clanton, T.L., Redox modulation of global phosphatase activity and protein phosphorylation in intact skeletal muscle. J. Physiol. 587 (2009), 5767–5781.
67. [67] Iwakoshi, N.N., Lee, A.H., Vallabhajosyula, P., Otipoby, K.L., Rajewsky, K., Glimcher, L.H., Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat. Immunol. 4 (2003), 321–329.
68. [68] Nicola, N.A., Babon, J.J., Leukemia inhibitory factor (LIF). Cytokine Growth Factor Rev. 26 (2015), 533–544.
69. [69] Broholm, C., Pedersen, B.K., Leukaemia inhibitory factor–an exercise-induced myokine. Exerc. Immunol. Rev. 16 (2010), 77–85.
70. [70] Barnard, W., Bower, J., Brown, M.A., Murphy, M., Austin, L., Leukemia inhibitory factor (LIF) infusion stimulates skeletal muscle regeneration after injury: injured muscle expresses lif mRNA. J. Neurol. Sci. 123 (1994), 108–113.
71. [71] Broholm, C., Mortensen, O.H., Nielsen, S., Akerstrom, T., Zankari, A., Dahl, B., Pedersen, B.K., Exercise induces expression of leukaemia inhibitory factor in human skeletal muscle. J. Physiol. 586 (2008), 2195–2201.
72. [72] Broholm, C., Laye, M.J., Brandt, C., Vadalasetty, R., Pilegaard, H., Pedersen, B.K., Scheele, C., LIF is a contraction-induced myokine stimulating human myocyte proliferation. J. Appl. Physiol. (1985) 111 (2011), 251–259.
73. [73] Spangenburg, E.E., Booth, F.W., Multiple signaling pathways mediate LIF-induced skeletal muscle satellite cell proliferation. Am. J. Physiol. Cell Physiol. 283 (2002), C204–C211.
74. [74] Hunt, L.C., Upadhyay, A., Jazayeri, J.A., Tudor, E.M., White, J.D., An anti-inflammatory role for leukemia inhibitory factor receptor signaling in regenerating skeletal muscle. Histochem. Cell Biol. 139 (2013), 13–34.
75. [75] Grabstein, K.H., Eisenman, J., Shanebeck, K., Rauch, C., Srinivasan, S., Fung, V., Beers, C., Richardson, J., Schoenborn, M.A., Ahdieh, M., et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264 (1994), 965–968.
76. [76] Quinn, L.S., Strait-Bodey, L., Anderson, B.G., Argiles, J.M., Havel, P.J., Interleukin-15 stimulates adiponectin secretion by 3T3-L1 adipocytes: evidence for a skeletal muscle-to-fat signaling pathway. Cell Biol. Int. 29 (2005), 449–457.
77. [77] Quinn, L.S., Anderson, B.G., Genetic Studies. J. Obes., 2011, 456347.
78. [78] Ye, J., e 2 diabetes. Front. Med. 9 (2015), 139–145.
79. [79] Tamura, Y., Watanabe, K., Kantani, T., Hayashi, J., Ishida, N., Kaneki, M., Upregulation of circulating IL-15 by treadmill running in healthy individuals: is IL-15 an endocrine mediator of the beneficial effects of endurance exercise?. Endocr. J. 58 (2011), 211–215.
80. [80] Quinn, L.S., Anderson, B.G., Conner, J.D., Wolden-Hanson, T., Marcell, T.J., IL-15 is required for postexercise induction of the pro-oxidative mediators PPARdelta and SIRT1 in male mice. Endocrinology 155 (2014), 143–155.
81. [81] Rinnov, A., Yfanti, C., Nielsen, S., Akerstrom, T.C., Peijs, L., Zankari, A., Fischer, C.P., Pedersen, B.K., Endurance training enhances skeletal muscle interleukin-15 in human male subjects. Endocrine 45 (2014), 271–278.
82. [82] McPherron, A.C., Lawler, A.M., Lee, S.J., Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387 (1997), 83–90.
83. [83] Allen, D.L., Hittel, D.S., McPherron, A.C., Expression and function of myostatin in obesity, diabetes, and exercise adaptation. Med. Sci. Sports Exerc. 43 (2011), 1828–1835.
84. [84] Latres, E., Pangilinan, J., Miloscio, L., Bauerlein, R., Na, E., Potocky, T.B., Huang, Y., Eckersdorff, M., Rafique, A., Mastaitis, J., Lin, C., Murphy, A.J., Yancopoulos, G.D., Gromada, J., Stitt, T., Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice. Skelet. Muscle, 5, 2015, 34.
85. [85] Becker, C., Lord, S.R., Studenski, S.A., Warden, S.J., Fielding, R.A., Recknor, C.P., Hochberg, M.C., Ferrari, S.L., Blain, H., Binder, E.F., Rolland, Y., Poiraudeau, S., Benson, C.T., Myers, S.L., Hu, L., Ahmad, Q.I., Pacuch, K.R., Gomez, E.V., Benichou, O., Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol., 2015.
86. [86] Seldin, M.M., Peterson, J.M., Byerly, M.S., Wei, Z., Wong, G.W., Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J. Biol. Chem. 287 (2012), 11968–11980.
87. [87] Seldin, M.M., Lei, X., Tan, S.Y., Stanson, K.P., Wei, Z., Wong, G.W., Skeletal muscle-derived myonectin activates the mammalian target of rapamycin (mTOR) pathway to suppress autophagy in liver. J. Biol. Chem. 288 (2013), 36073–36082.
88. [88] Gamas, L., Matafome, P., Seica, R., Irisin and myonectin regulation in the insulin resistant muscle: implications to adipose tissue: muscle crosstalk. J. Diabetes Res., 2015, 2015, 359159.
89. [89] Albrecht, E., Norheim, F., Thiede, B., Holen, T., Ohashi, T., Schering, L., Lee, S., Brenmoehl, J., Thomas, S., Drevon, C.A., Erickson, H.P., Maak, S., Irisin – a myth rather than an exercise-inducible myokine. Sci. Rep., 5, 2015, 8889.
90. [90] Raschke, S., Elsen, M., Gassenhuber, H., Sommerfeld, M., Schwahn, U., Brockmann, B., Jung, R., Wisloff, U., Tjonna, A.E., Raastad, T., Hallen, J., Norheim, F., Drevon, C.A., Romacho, T., Eckardt, K., Eckel, J., Evidence against a beneficial effect of irisin in humans. PLoS One, 8, 2013, e73680.
91. [91] Jedrychowski, M.P., Wrann, C.D., Paulo, J.A., Gerber, K.K., Szpyt, J., Robinson, M.M., Nair, K.S., Gygi, S.P., Spiegelman, B.M., Detection and quantitation of circulating human irisin by tandem mass spectrometry. Cell Metab., 2015.
92. [92] Ruas, J.L., White, J.P., Rao, R.R., Kleiner, S., Brannan, K.T., Harrison, B.C., Greene, N.P., Wu, J., Estall, J.L., Irving, B.A., Lanza, I.R., Rasbach, K.A., Okutsu, M., Nair, K.S., Yan, Z., Leinwand, L.A., Spiegelman, B.M., A PGC-1alpha isoform induced by resistance training regulates skeletal muscle hypertrophy. Cell 151 (2012), 1319–1331.
93. [93] Ushach, I., Burkhardt, A.M., Martinez, C., Hevezi, P.A., Gerber, P.A., Buhren, B.A., Schrumpf, H., Valle-Rios, R., Vazquez, M.I., Homey, B., Zlotnik, A., METEORIN-LIKE is a cytokine associated with barrier tissues and alternatively activated macrophages. Clin. Immunol. 156 (2015), 119–127.
94. [94] Bertrand, C., Valet, P., Castan-Laurell, I., Apelin and energy metabolism. Front Physiol., 6, 2015, 115.
95. [95] Besse-Patin, A., Montastier, E., Vinel, C., Castan-Laurell, I., Louche, K., Dray, C., Daviaud, D., Mir, L., Marques, M.A., Thalamas, C., Valet, P., Langin, D., Moro, C., Viguerie, N., Effect of endurance training on skeletal muscle myokine expression in obese men: identification of apelin as a novel myokine. Int. J. Obes. (Lond.) 38 (2014), 707–713.
96. [96] Hamilton, G., Rath, B., Burghuber, O., Chitinase-3-like-1/YKL-40 as marker of circulating tumor cells. Transl. Lung Cancer Res. 4 (2015), 287–291.
97. [97] Gorgens, S.W., Eckardt, K., Elsen, M., Tennagels, N., Eckel, J., Chitinase-3-like protein 1 protects skeletal muscle from TNFalpha-induced inflammation and insulin resistance. Biochem. J. 459 (2014), 479–488.
98. [98] Lee, C.G., Da Silva, C.A., Dela Cruz, C.S., Ahangari, F., Ma, B., Kang, M.J., He, C.H., Takyar, S., Elias, J.A., Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu. Rev. Physiol. 73 (2011), 479–501.
99. [99] Brandan, E., Fuentes, M.E., Andrade, W., The proteoglycan decorin is synthesized and secreted by differentiated myotubes. Eur. J. Cell Biol. 55 (1991), 209–216.
100. [100] Kjaer, M., Role of extracellular matrix in adaptation of tendon and skeletal muscle to mechanical loading. Physiol. Rev. 84 (2004), 649–698.
101. [101] Thomas, K., Engler, A.J., Meyer, G.A., Extracellular matrix regulation in the muscle satellite cell niche. Connect Tissue Res. 56 (2015), 1–8.
102. [102] Timmons, J.A., Jansson, E., Fischer, H., Gustafsson, T., Greenhaff, P.L., Ridden, J., Rachman, J., Sundberg, C.J., Modulation of extracellular matrix genes reflects the magnitude of physiological adaptation to aerobic exercise training in humans. BMC Biol., 3, 2005, 19.
103. [103] Heinemeier, K.M., Bjerrum, S.S., Schjerling, P., Kjaer, M., Expression of extracellular matrix components and related growth factors in human tendon and muscle after acute exercise. Scand. J. Med. Sci. Sports 23 (2013), e150–e161.
104. [104] Kanzleiter, T., Rath, M., Gorgens, S.W., Jensen, J., Tangen, D.S., Kolnes, A.J., Kolnes, K.J., Lee, S., Eckel, J., Schurmann, A., Eckardt, K., The myokine decorin is regulated by contraction and involved in muscle hypertrophy. Biochem. Biophys. Res. Commun. 450 (2014), 1089–1094.
105. [105] Bradshaw, A.D., Diverse biological functions of the SPARC family of proteins. Int. J. Biochem. Cell. Biol. 44 (2012), 480–488.
106. [106] Frangogiannis, N.G., Matricellular proteins in cardiac adaptation and disease. Physiol. Rev. 92 (2012), 635–688.
107. [107] Aoi, W., Naito, Y., Takagi, T., Tanimura, Y., Takanami, Y., Kawai, Y., Sakuma, K., Hang, L.P., Mizushima, K., Hirai, Y., Koyama, R., Wada, S., Higashi, A., Kokura, S., Ichikawa, H., Yoshikawa, T., A novel myokine, secreted protein acidic and rich in cysteine (SPARC), suppresses colon tumorigenesis via regular exercise. Gut 62 (2013), 882–889.
108. [108] Son, J.S., Kim, J.H., Kim, H.J., Yoon, D.H., Kim, J.S., Song, H.S., Song, W., Effect of resistance ladder training on SPARC expression in skeletal muscle of hindlimb immobilized rats. Muscle Nerve, 2015.
109. [109] Ost, M., Keipert, S., van Schothorst, E.M., Donner, V., van der Stelt, I., Kipp, A.P., Petzke, K.J., Jove, M., Pamplona, R., Portero-Otin, M., Keijer, J., Klaus, S., Muscle mitohormesis promotes cellular survival via serine/glycine pathway flux. FASEB J. 29 (2015), 1314–1328.
110. [110] Kharitonenkov, A., Shiyanova, T.L., Koester, A., Ford, A.M., Micanovic, R., Galbreath, E.J., Sandusky, G.E., Hammond, L.J., Moyers, J.S., Owens, R.A., Gromada, J., Brozinick, J.T., Hawkins, E.D., Wroblewski, V.J., Li, D.S., Mehrbod, F., Jaskunas, S.R., Shanafelt, A.B., FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115 (2005), 1627–1635.
111. [111] Woo, Y.C., Xu, A., Wang, Y., Lam, K.S., Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin. Endocrinol. 78 (2013), 489–496.
112. [112] Murata, Y., Konishi, M., Itoh, N., FGF21 as an endocrine regulator in lipid metabolism: from molecular evolution to physiology and pathophysiology. J. Nutr. Metab., 2011, 2011, 981315.
113. [113] Kharitonenkov, A., Adams, A.C., Inventing new medicines: the FGF21 story. Mol. Metab. 3 (2014), 221–229.
114. [114] Zhang, J., Li, Y., Fibroblast growth factor 21 analogs for treating metabolic disorders. Front Endocrinol. (Lausanne), 6, 2015, 168.
115. [115] Giralt, M., Gavalda-Navarro, A., Villarroya, F., Fibroblast growth factor-21, energy balance and obesity. Mol. Cell Endocrinol., 2015.
116. [116] Hanks, L.J., Gutierrez, O.M., Bamman, M.M., Ashraf, A., McCormick, K.L., Casazza, K., Circulating levels of fibroblast growth factor-21 increase with age independently of body composition indices among healthy individuals. J. Clin. Transl. Endocrinol. 2 (2015), 77–82.
117. [117] Zhang, X., Yeung, D.C., Karpisek, M., Stejskal, D., Zhou, Z.G., Liu, F., Wong, R.L., Chow, W.S., Tso, A.W., Lam, K.S., Xu, A., Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57 (2008), 1246–1253.
118. [118] Berti, L., Irmler, M., Zdichavsky, M., Meile, T., Bohm, A., Stefan, N., Fritsche, A., Beckers, J., Konigsrainer, A., Haring, H.U., de Angelis, M.H., Staiger, H., Fibroblast growth factor 21 is elevated in metabolically unhealthy obesity and affects lipid deposition, adipogenesis, and adipokine secretion of human abdominal subcutaneous adipocytes. Mol. Metab. 4 (2015), 519–527.
119. [119] Mashili, F.L., Austin, R.L., Deshmukh, A.S., Fritz, T., Caidahl, K., Bergdahl, K., Zierath, J.R., Chibalin, A.V., Moller, D.E., Kharitonenkov, A., Krook, A., Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes/metabolism Res. Rev. 27 (2011), 286–297.
120. [120] Shen, Y., Ma, X., Zhou, J., Pan, X., Hao, Y., Zhou, M., Lu, Z., Gao, M., Bao, Y., Jia, W., Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovascular Diabetol., 12, 2013, 124.
121. [121] Kim, K.H., Lee, M.S., FGF21 as a mediator of adaptive responses to stress and metabolic benefits of anti-diabetic drugs. J. Endocrinol. 226 (2015), R1–16.
122. [122] Nishimura, T., Nakatake, Y., Konishi, M., Itoh, N., Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta 1492 (2000), 203–206.
123. [123] Badman, M.K., Pissios, P., Kennedy, A.R., Koukos, G., Flier, J.S., Maratos-Flier, E., Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 5 (2007), 426–437.
124. [124] Izumiya, Y., Bina, H.A., Ouchi, N., Akasaki, Y., Kharitonenkov, A., Walsh, K., FGF21 is an Akt-regulated myokine. FEBS Lett. 582 (2008), 3805–3810.
125. [125] Itoh, N., FGF21 as a hepatokine, adipokine, and myokine in metabolism and diseases. Front. Endocrinol. (Lausanne), 5, 2014, 107.
126. [126] Ding, X., Boney-Montoya, J., Owen, B.M., Bookout, A.L., Coate, K.C., Mangelsdorf, D.J., Kliewer, S., A. betaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 16 (2012), 387–393.
127. [127] Adams, A.C., Cheng, C.C., Coskun, T., Kharitonenkov, A., FGF21 Requires betaklotho to Act In Vivo. PLoS One, 7, 2012, e49977.
128. [128] Ogawa, Y., Kurosu, H., Yamamoto, M., Nandi, A., Rosenblatt, K.P., Goetz, R., Eliseenkova, A.V., Mohammadi, M., Kuro-o, M., BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl. Acad. Sci. USA 104 (2007), 7432–7437.
129. [129] Hojman, P., Pedersen, M., Nielsen, A.R., Krogh-Madsen, R., Yfanti, C., Akerstrom, T., Nielsen, S., Pedersen, B.K., Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes 58 (2009), 2797–2801.
130. [130] Cuevas-Ramos, D., Almeda-Valdes, P., Meza-Arana, C.E., Brito-Cordova, G., Gomez-Perez, F.J., Mehta, R., Oseguera-Moguel, J., Aguilar-Salinas, C.A., Exercise increases serum fibroblast growth factor 21 (FGF21) levels. PLoS One, 7, 2012, e38022.
131. [131] Kim, K.H., Kim, S.H., Min, Y.K., Yang, H.M., Lee, J.B., Lee, M.S., Acute exercise induces FGF21 expression in mice and in healthy humans. PLoS One, 8, 2013, e63517.
132. [132] Hansen, J.S., Clemmesen, J.O., Secher, N.H., Hoene, M., Drescher, A., Weigert, C., Pedersen, B.K., Plomgaard, P., Glucagon-to-insulin ratio is pivotal for splanchnic regulation of FGF-21 in humans. Mol. Metab. 4 (2015), 551–560.
133. [133] Keipert, S., Klaus, S., Heldmaier, G., Jastroch, M., UCP1 ectopically expressed in murine muscle displays native function and mitigates mitochondrial superoxide production. Biochim. Biophys. Acta 1797 (2010), 324–330.
134. [134] Tsai, S., Sitzmann, J.M., Dastidar, S.G., Rodriguez, A.A., Vu, S.L., McDonald, C.E., Academia, E.C., O'Leary, M.N., Ashe, T.D., La Spada, A.R., Kennedy, B.K., Muscle-specific 4E-BP1 signaling activation improves metabolic parameters during aging and obesity. J. Clin. Invest. 125 (2015), 2952–2964.
135. [135] Guridi, M., Tintignac, L.A., Lin, S., Kupr, B., Castets, P., Ruegg, M.A., Activation of mTORC1 in skeletal muscle regulates whole-body metabolism through FGF21. ra113 Sci. Signal, 8, 2015.
136. [136] Crooks, D.R., Natarajan, T.G., Jeong, S.Y., Chen, C., Park, S.Y., Huang, H., Ghosh, M.C., Tong, W.H., Haller, R.G., Wu, C., Rouault, T.A., Elevated FGF21 secretion, PGC-1alpha and ketogenic enzyme expression are hallmarks of iron-sulfur cluster depletion in human skeletal muscle. Hum. Mol. Genet. 23 (2014), 24–39.
137. [137] Suomalainen, A., Elo, J.M., Pietilainen, K.H., Hakonen, A.H., Sevastianova, K., Korpela, M., Isohanni, P., Marjavaara, S.K., Tyni, T., Kiuru-Enari, S., Pihko, H., Darin, N., Ounap, K., Kluijtmans, L.A., Paetau, A., Buzkova, J., Bindoff, L.A., Annunen-Rasila, J., Uusimaa, J., Rissanen, A., Yki-Jarvinen, H., Hirano, M., Tulinius, M., Smeitink, J., Tyynismaa, H., FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol. 10 (2011), 806–818.
138. [138] Ost, M., Coleman, V., Voigt, A., Van Schothorst, E.M., Keipert, S., Van der Stelt, I., Ringel, S., Graja, A., Ambrosi, T., Kipp, A.P., Jastroch, M., Schulz, T.J., Keijer, J., Klaus, S., Muscle mitochondrial stress adaptation operates independently of endogenous FGF21 action. Mol. Metab. 5 (2016), 79–90.
139. [139] Veniant, M.M., Hale, C., Helmering, J., Chen, M.M., Stanislaus, S., Busby, J., Vonderfecht, S., Xu, J., Lloyd, D.J., FGF21 promotes metabolic homeostasis via white adipose and leptin in mice. PLoS One, 7, 2012, e40164.
140. [140] Adams, A.C., Yang, C., Coskun, T., Cheng, C.C., Gimeno, R.E., Luo, Y., Kharitonenkov, A., The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Mol. Metab. 2 (2012), 31–37.
141. [141] Fisher, F.M., Kleiner, S., Douris, N., Fox, E.C., Mepani, R.J., Verdeguer, F., Wu, J., Kharitonenkov, A., Flier, J.S., Maratos-Flier, E., Spiegelman, B.M., FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 26 (2012), 271–281.
142. [142] Keipert, S., Voigt, A., Klaus, S., Dietary effects on body composition, glucose metabolism, and longevity are modulated by skeletal muscle mitochondrial uncoupling in mice. Aging Cell 10 (2011), 122–136.
143. [143] Kempf, T., Eden, M., Strelau, J., Naguib, M., Willenbockel, C., Tongers, J., Heineke, J., Kotlarz, D., Xu, J., Molkentin, J.D., Niessen, H.W., Drexler, H., Wollert, K.C., The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ. Res. 98 (2006), 351–360.
144. [144] Corre, J., Hebraud, B., Bourin, P., Concise review: growth differentiation factor 15 in pathology: a clinical role?. Stem Cells Transl. Med. 2 (2013), 946–952.
145. [145] Adela, R., Banerjee, S.K., GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. J. Diabetes Res., 2015, 2015, 490842.
146. [146] Ebner, N., Steinbeck, L., Doehner, W., Anker, S.D., von Haehling, S., Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies. J. Cachexia Sarcopenia Muscle 5 (2014), 27–34.
147. [147] Bloch, S.A., Lee, J.Y., Syburra, T., Rosendahl, U., Griffiths, M.J., Kemp, P.R., Polkey, M.I., Increased expression of GDF-15 may mediate ICU-acquired weakness by down-regulating muscle microRNAs. Thorax 70 (2015), 219–228.
148. [148] Johnen, H., Lin, S., Kuffner, T., Brown, D.A., Tsai, V.W., Bauskin, A.R., Wu, L., Pankhurst, G., Jiang, L., Junankar, S., Hunter, M., Fairlie, W.D., Lee, N.J., Enriquez, R.F., Baldock, P.A., Corey, E., Apple, F.S., Murakami, M.M., Lin, E.J., Wang, C., During, M.J., Sainsbury, A., Herzog, H., Breit, S.N., Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat. Med. 13 (2007), 1333–1340.
149. [149] Breit, S.N., Johnen, H., Cook, A.D., Tsai, V.W., Mohammad, M.G., Kuffner, T., Zhang, H.P., Marquis, C.P., Jiang, L., Lockwood, G., Lee-Ng, M., Husaini, Y., Wu, L., Hamilton, J.A., Brown, D.A., The TGF-beta superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors 29 (2011), 187–195.
150. [150] Park, S.H., Choi, H.J., Yang, H., Do, K.H., Kim, J., Kim, H.H., Lee, H., Oh, C.G., Lee, D.W., Moon, Y., Two in-and-out modulation strategies for endoplasmic reticulum stress-linked gene expression of pro-apoptotic macrophage-inhibitory cytokine 1. J. Biol. Chem. 287 (2012), 19841–19855.
151. [151] Macia, L., Tsai, V.W., Nguyen, A.D., Johnen, H., Kuffner, T., Shi, Y.C., Lin, S., Herzog, H., Brown, D.A., Breit, S.N., Sainsbury, A., Macrophage inhibitory cytokine 1 (MIC-1/GDF15) decreases food intake, body weight and improves glucose tolerance in mice on normal & obesogenic diets. PLoS One, 7, 2012, e34868.
152. [152] Chrysovergis, K., Wang, X., Kosak, J., Lee, S.H., Kim, J.S., Foley, J.F., Travlos, G., Singh, S., Baek, S.J., Eling, T.E., NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism. Int. J. Obes. (London) 38 (2014), 1555–1564.
153. [153] Tsai, V.W., Macia, L., Johnen, H., Kuffner, T., Manadhar, R., Jorgensen, S.B., Lee-Ng, K.K., Zhang, H.P., Wu, L., Marquis, C.P., Jiang, L., Husaini, Y., Lin, S., Herzog, H., Brown, D.A., Sainsbury, A., Breit, S.N., TGF-b superfamily cytokine MIC-1/GDF15 is a physiological appetite and body weight regulator. PLoS One, 8, 2013, e55174.
154. [154] Kalko, S.G., Paco, S., Jou, C., Rodriguez, M.A., Meznaric, M., Rogac, M., Jekovec-Vrhovsek, M., Sciacco, M., Moggio, M., Fagiolari, G., De Paepe, B., De Meirleir, L., Ferrer, I., Roig-Quilis, M., Munell, F., Montoya, J., Lopez-Gallardo, E., Ruiz-Pesini, E., Artuch, R., Montero, R., Torner, F., Nascimento, A., Ortez, C., Colomer, J., Jimenez-Mallebrera, C., Transcriptomic profiling of TK2 deficient human skeletal muscle suggests a role for the p53 signalling pathway and identifies growth and differentiation factor-15 as a potential novel biomarker for mitochondrial myopathies. BMC Genomics, 15, 2014, 91.
155. [155] Sanchis-Gomar, F., Bonaguri, C., Aloe, R., Pareja-Galeano, H., Martinez-Bello, V., Gomez-Cabrera, M.C., Candel, J., Vina, J., Lippi, G., Effects of acute exercise and xanthine oxidase inhibition on novel cardiovascular biomarkers. Transl. Res. 162 (2013), 102–109.
156. [156] Galliera, E., Lombardi, G., Marazzi, M.G., Grasso, D., Vianello, E., Pozzoni, R., Banfi, G., Corsi Romanelli, M.M., Acute exercise in elite rugby players increases the circulating level of the cardiovascular biomarker GDF-15. Scand. J. Clin. Lab Invest. 74 (2014), 492–499.
157. [157] Tchou, I., Margeli, A., Tsironi, M., Skenderi, K., Barnet, M., Kanaka-Gantenbein, C., Papassotiriou, I., Beris, P., Growth-differentiation factor-15, endoglin and N-terminal pro-brain natriuretic peptide induction in athletes participating in an ultramarathon foot race. Biomarkers 14 (2009), 418–422.
158. [158] Nishizawa, H., Matsuda, M., Yamada, Y., Kawai, K., Suzuki, E., Makishima, M., Kitamura, T., Shimomura, I., Musclin, a novel skeletal muscle-derived secretory factor. J. Biol. Chem. 279 (2004), 19391–19395.
159. [159] Banzet, S., Koulmann, N., Sanchez, H., Serrurier, B., Peinnequin, A., Bigard, A.X., Musclin gene expression is strongly related to fast-glycolytic phenotype. Biochem. Biophys. Res. Commun. 353 (2007), 713–718.
160. [160] Liu, Y., Huo, X., Pang, X.F., Zong, Z.H., Meng, X., Liu, G.L., Musclin inhibits insulin activation of Akt/protein kinase B in rat skeletal muscle. J. Int. Med. Res. 36 (2008), 496–504.
161. [161] Li, Y.X., Cheng, K.C., Asakawa, A., Kato, I., Sato, Y., Amitani, H., Kawamura, N., Cheng, J.T., Inui, A., Role of musclin in the pathogenesis of hypertension in rat. PLoS One, 8, 2013, e72004.
162. [162] Sierra, A., Subbotina, E., Zhu, Z., Gao, Z., Koganti, S.R., Coetzee, W., Goldhamer, D., Hodgson-Zingman, D.M., Zingman, L.V., Disruption of ATP-sensitive potassium channel function in skeletal muscles promotes production and secretion of musclin Condensed title: Skeletal muscle I regulates musclin. Biochem. Biophys. Res. Commun., 2016.
163. [163] Subbotina, E., Sierra, A., Zhu, Z., Gao, Z., Koganti, S.R., Reyes, S., Stepniak, E., Walsh, S.A., Acevedo, M.R., Perez-Terzic, C.M., Hodgson-Zingman, D.M., Zingman, L.V., Musclin is an activity-stimulated myokine that enhances physical endurance. Proc. Natl. Acad. Sci. USA 112 (2015), 16042–16047.
164. [164] Lira, F.S., Antunes Bde, M., Seelaender, M., Neto, J.C., The therapeutic potential of exercise to treat cachexia. Curr. Opin. Support Palliat. Care 9 (2015), 317–324.
165. [165] Inagaki, T., Regulation and Physiological Functions of FGF21 and its Association with NAFLD. Front Endocrinol. (Lausanne), 6, 2015, 147.
166. [166] Hamrick, M.W., A role for myokines in muscle-bone interactions. Exerc. Sport Sci. Rev. 39 (2011), 43–47.
167. [167] Matthews, V.B., Astrom, M.B., Chan, M.H., Bruce, C.R., Krabbe, K.S., Prelovsek, O., Akerstrom, T., Yfanti, C., Broholm, C., Mortensen, O.H., Penkowa, M., Hojman, P., Zankari, A., Watt, M.J., Bruunsgaard, H., Pedersen, B.K., Febbraio, M.A., Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP-activated protein kinase. Diabetologia 52 (2009), 1409–1418.
168. [168] Kainulainen, H., CHI3L1 – a novel myokine. Acta Physiol. (Oxf), 2015.
169. [169] Crane, J.D., MacNeil, L.G., Lally, J.S., Ford, R.J., Bujak, A.L., Brar, I.K., Kemp, B.E., Raha, S., Steinberg, G.R., Tarnopolsky, M.A., Exercise-stimulated interleukin-15 is controlled by AMPK and regulates skin metabolism and aging. Aging Cell 14 (2015), 625–634.
170. [170] Huh, J.Y., Panagiotou, G., Mougios, V., Brinkoetter, M., Vamvini, M.T., Schneider, B.E., Mantzoros, C.S., FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 61 (2012), 1725–1738.
171. [171] Sanchis-Gomar, F., Perez-Quilis, C., The p38-PGC-1alpha-irisin-betatrophin axis: exploring new pathways in insulin resistance. Adipocyte 3 (2014), 67–68.
172. [172] Baeza-Raja, B., Munoz-Canoves, P., p38 MAPK-induced nuclear factor-kappaB activity is required for skeletal muscle differentiation: role of interleukin-6. Mol. Biol. Cell 15 (2004), 2013–2026.
173. [173] Leick, L., Hellsten, Y., Fentz, J., Lyngby, S.S., Wojtaszewski, J.F., Hidalgo, J., Pilegaard, H., PGC-1alpha mediates exercise-induced skeletal muscle VEGF expression in mice. Am. J. Physiol. Endocrinol. Metab. 297 (2009), E92–103.
174. [174] Abruzzo, P.M., Esposito, F., Marchionni, C., di Tullio, S., Belia, S., Fulle, S., Veicsteinas, A., Marini, M., Moderate exercise training induces ROS-related adaptations to skeletal muscles. Int. J. Sports Med. 34 (2013), 676–687.